


Cite this: *RSC Adv.*, 2018, 8, 5936

Semi-rational screening of the inhibitors and β -lactam antibiotics against the New Delhi metallo- β -lactamase 1 (NDM-1) producing *E. coli*

Juan Wang,[†] Yang Li,[†] Haizhong Yan, Juan Duan, Xihua Luo, Xueqin Feng, Lanfen Lu and Weijia Wang ^{*}

Bacteria containing *bla*_{NDM-1} gene are a growing threat to almost all clinically β -lactam antibiotics. Especially, the New Delhi metallo- β -lactamase (NDM-1) has become a potential public survival risk. In this study, a novel and efficient strategy for inhibitors and β -lactam antibiotics screening using recombinant New Delhi metallo-beta-lactamase (NDM-1) was developed. First, the gene of *bla*_{NDM-1} were identified and cloned from multi-drug resistance of *Acinetobacter baumannii* isolate; by the means of protein expression and purification, recombinant NDM-1 activity was up to 68.5 U ml⁻¹, and high purity NDM-1 protein with activity of 347.4 U mg⁻¹ was obtained. Finally, for NDM-1, the inhibitors (aspergillomarasmine A (AMA) and EDTA) with high affinity (HI) and the β -lactam antibiotics (imipenem) with low affinity (LA) were screened out. Surprisingly, the inhibition of the NDM-1 was enhanced by the use of inhibitor combinations (AMA–EDTA (1 : 2)), where the IC₅₀ of AMA–EDTA was reduced by 88% and 95%, respectively, comparing to the AMA and EDTA alone. More interesting, AMA–EDTA could restore the activity of imipenem when tested against NDM-1 expressing strains (*E. coli* and *Acinetobacter baumannii*), with a working time of 120 min and 330 min, respectively. This method is expected to be used in high-throughput screening, drug redesign (including new inhibitors and drugs) and “old drug new use”.

Received 25th November 2017
Accepted 1st February 2018

DOI: 10.1039/c7ra12778b

rsc.li/rsc-advances

1. Introduction

Antibiotics play an important role in disease treatment of animals and humans in the past few years. Tens of thousands of lives have been saved by the high efficacy and low toxicity of β -lactam antibiotics. However, as a large number of antibiotic abuse and resistance screening, pathogens equipped with drug resistance weapons fight against mankind. Nowadays, multidrug-resistant (MDR) pathogens infections are becoming a real threat to international public health.¹ Since the emergence of multidrug-resistant strains, the difficulty of clinical treatment and medication are increasing, the health of animal and humans are in risk seriously. Therefore, mechanism of drug resistance of the MDR have been revealed. Research shows, the expression of β -lactamase is the most common mechanism of resistance in drug-resistant bacteria.²

β -Lactamases has the ability of hydrolysis the C–N bond of lactam ring of lactam antibiotics, leading the antibiotics inactive.³ β -Lactamases has been classified into two categories: serine- β -lactamases (SBLs) and metallo- β -lactamases (MBLs).⁴

Of those, serine- β -lactamases (SBLs) can be inhibited by many inhibitors, including the clavulanic acid, sulbactam, tazobactam and avibactam in clinical trials.⁵ Due to their extensive substrate spectrum and high activity, MBLs is more dangerous to human beings and pose an increasing public health risk.⁶ Bacteria equipped with MBLs can degrade a large number of β -lactams, such as penicillin, cephalosporin, carbapenems, and aztreonam.⁷ Bacteria with MBLs infections become a major public health problem worldwide.

The New Delhi metallo- β -lactamase 1 (NDM-1) is a new member of MBLs, and has rapidly emerged as the leading threat to the treatment of infections. The NDM-1 encoded by the *bla*_{NDM-1} gene was initially identified in a *Klebsiella pneumonia* isolate in 2008.⁸ Since then, NDM-1 has been found at least 180 variants in different strains, including *Escherichia coli*,⁹ *Acinetobacter baumannii*,¹⁰ *Vibrio cholera*, *Stenotrophomonas maltophilia* and *Pseudomonas putida*.¹¹ What's worse, few antibiotics can be used for the treatment of patients, who was infected by the bacteria carrying of NDM-1.¹²

Currently, there are two strategies to preserve the efficacy of β -lactam antibiotics for the NDM-1-producing strains: (I) discover or redesign new β -lactam antibiotics, that can avoid to be hydrolyzed by NDM-1, however, it will takes a long time; (II) inhibit NDM-1 activity, resulting the partner β -lactam antibiotics can work properly interfering with the formation of

Laboratory Medicine Department, Zhongshan People's Hospital, The Affiliated Hospital of Sun Yat-Sen University, Guangdong Province, No. 2 Sun Wen East Road, Zhongshan, Guangdong 528403, China. E-mail: wangweijia2017@sina.cn

[†] The co-first authors.



bacterial cell walls, which has been regarded as the quick and efficient route. In order to ensure activity of antibiotics (efficacy), efficient and safe inhibitors are urgently needed to overcome the activity of NDM-1. However, NDM-1 are not susceptible to the SBLs' inhibitors, various structurally types of inhibitors have been described with no effect, including carboxylic/succinic acids,¹³ triazoles/tetrazoles,¹⁴ thiols,¹⁵ trifluoromethyl ketones and others.¹⁶ NDM-1-mediated resistance to β -lactam antibiotics emerged as a clinical threat to life-saving.

Therefore, the key issue is how to obtain the inhibitors for NDM-1 inhibition, assisting the antibiotics against the multidrug-resistant strains harboring *bla*_{NDM-1} gene, synergistically. In the present study, the NDM-1-encoding gene from *Acinetobacter baumannii* was overexpressed in *Escherichia coli*, optimal expression conditions and the physical and chemical properties of NDM-1 were then identified. The aim is to obtain a best inhibitor to inhibit NDM-1 activity and combine the inhibitor with excellent antibiotics to against NDM-1 producing strains. A novel and efficient strategy for inhibitors and β -lactam antibiotics screening using recombinant New Delhi metallo-beta-lactamase (NDM-1) was developed.

2. Materials and Methods

2.1. Materials bacterial strains, plasmids, and enzymes

Chemicals and solvents were purchased from standard suppliers and used without further purification. Ampicillin, penicillin G and piperacillin were purchased from Sangon Biotechnology Co. Ltd (Shanghai, China); cefuroxime, ceftizoxime, cefpiramide, ceftazidime, cefoxitin, cefaclor, cephalixin, nitrocefin, cefepime, cephalothin, cefotaxime, imipenem and meropenem were purchased from TCI (Shanghai, China); inhibitors were purchased from Sigma-Aldrich Corporation (USA). The host strain *Escherichia coli* BL21 (DE3), *E. coli* JM109 [recA supE hsr Δ (lac-pro)] and the expression plasmid pET-28a (+) were obtained from Novagen (Madison, WI, USA). LATAq DNA and PrimeSTAR DNA polymerase were from TaKaRa (Dalian, China). The T-vector, restriction enzymes, T₄-ligase, plasmid miniprep kit, and agarose gel DNA purification kit were supplied by TaKaRa Biotechnology (Otsu, Japan).

2.2. Expression of the New Delhi metallo- β -lactamase 1 (NDM-1) in *E. coli* BL21 (DE3)

Acinetobacter baumannii isolates from four general hospitals in the Guangzhou area of China during June 2012 and June 2016. Complete DNA of *Acinetobacter baumannii* S002 was used as template. The *bla*_{NDM-1} gene was amplified by polymerase chain reaction (PCR) using the following primers: 5'-CG GGATCC ATGGAATTGCCAATATTATG-3' (forward) and 5'-CCG CTCGAG TCAGCGCAGCTTGTCGCCATG-3' (reverse; the underlined regions are BamHI and XhoI restriction sites, respectively). PCR parameters: initial denaturation at 95 °C for 5 min; denaturation at 94 °C for 1 min, annealing at 60 °C for 1 min, extension at 72 °C for 1.2 min, repeated for 30 cycles; final extension step at 72 °C for 2 min. The resulting PCR

product was purified with a SanPrep Column PCR Product Purification Kit (Sangon Biotech Co. Ltd., Shanghai, China). The purified PCR product and the T₇-based expression vector pET28a (+) (Novagen, Madison, Wisconsin) were digested with BamHI and XhoI for 4 h at 37 °C, respectively. The digested product purified using a SanPrep Column PCR product purification Kit, and ligated using T₄-DNA ligase at 16 °C 24 h. The ligation mixture was transformed to *E. coli* JM109 (Novagen, Madison, WI), and transformants were selected for growth on solid Luria-Bertane (LB) agar plates containing kanamycin (50 μ g ml⁻¹) and 0.05 M Zn²⁺. Positive clones were validated by PCR using the primers 5'-ATCGTCAGGGATGGCGGCCGCG-3' (forward) and 5'-TGCGACATCGTATAACGTTACTGGT-3' (reverse). The final plasmid, pET28a-NDM-1, purified from a single colony was identified by sequencing (Sangon Biotech, Shanghai). The correct pET28a-NDM-1 was transformed into *E. coli* BL21 (DE3).

2.3. Media and culture conditions

E. coli containing pET28a (+)-*bla*_{NDM-1} was cultured in the following medium. Lysogeny broth (LB): 10 g L⁻¹ peptone, 5 g L⁻¹ yeast extract, and 10 g L⁻¹ NaCl, pH 7.0. Lysogeny broth auto-induction medium (LBA): 0.5 g L⁻¹ glucose, 2 g L⁻¹ lactose, 5 g L⁻¹ glycerol, 10 g L⁻¹ peptone, 5 g L⁻¹ yeast extract, 10 g L⁻¹ NaCl, 6.5 g L⁻¹ KH₂PO₄, 7.0 g L⁻¹ Na₂HPO₄, 3.3 g L⁻¹ (NH₄)₂SO₄, and 0.15 g L⁻¹ MgSO₄; pH 7.0. Terrific broth (TB): 5 ml L⁻¹ glycerol, 12 g L⁻¹ tryptone, 25 g L⁻¹ yeast extract, 2.31 g L⁻¹ KH₂PO₄, and 12.54 g L⁻¹ K₂HPO₄; pH 7.0. Super broth (SB): 35 g L⁻¹ tryptone, 20 g L⁻¹ yeast extract, 5 g L⁻¹ glycerol, 2.31 g L⁻¹ KH₂PO₄, and 12.54 g L⁻¹ K₂HPO₄; pH 7.0. SOC medium: 20 g L⁻¹ peptone, 5.0 g L⁻¹ yeast extract, 0.5 g L⁻¹ NaCl, 0.2 g L⁻¹ KCl, 0.01 g L⁻¹ ZnCl₂, 1.0 g L⁻¹ MgCl₂ and 4 g L⁻¹ glucose, pH 7.0. The seed culture was incubated on a reciprocal shaker (200 rpm) at 37 °C in a 500 ml flask containing 50 ml of LB medium (50 μ g ml⁻¹ kanamycin) for 16 h. The prepared seed culture was inoculated (5%, v/v) into the fresh medium. *Acinetobacter baumannii* was grown in nutrient broth (2 g yeast extract, 1 g meat extract, 5 g peptone and 5 g of NaCl in 1 L of sterile distilled water, 15.0 g agar).¹⁷ *E. coli* JM109 was used as the host for plasmid amplification. *E. coli* was incubated in lysogeny broth (LB) medium at 37 °C, 200 rpm, for 24 h.

2.4. Purification of recombinant NDM-1

NDM-1 were produced in *E. coli* BL21 (DE3)-pET28a (+)-*bla*_{NDM-1} cells at 37 °C using SOC medium supplemented with 50 μ g ml⁻¹ kanamycin. NDM-1 expression was induced by IPTG (0.65 mM final concentration), while the OD₆₀₀ reached 0.6. At this point the temperature was adjusted to 25 °C and the cells were further incubated for 20 h. The culture broth was centrifuged at 12 000 rpm for 15 min. The cells were suspended in 0.1 M phosphate buffer (PBS, pH 7.2), and sonicated by an Ultrasonic Cell Disruptor (power 400 W, working 4 s, pause 8 s, total 40 min). The supernatant was concentrated by ultrafiltration with an Amicon Ultra-15 10 K device (Millipore, USA), those proteins with a molecular mass below 10 kDa has been removed. Recombinant NDM-1 were purified using nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen, Hilden, Germany). His tags were



digested with TurboTEV protease (Accelagen, San Diego, CA). The purities of NDM-1 was estimated by SDS-PAGE. The purified recombinant NDM-1 was prepared for the further study of the activity, inhibitor screening. The protein concentration was determined using Bradford's method, with bovine serum albumin (BSA) as the standard.¹⁸

2.5. Measurement of NDM-1 activity and antimicrobial susceptibility testing

NDM-1 activity was measured based on the method reported by O'Callaghan *et al.*¹⁹ The reaction mixture containing 200 μ M nitrocefin (Sigma-Aldrich) and enzymes 100 μ L were incubated with 50 mM Bis-Tris buffer (pH 6.5) containing 50 μ M Zn²⁺, 1 mM 1,4-dithio-DL-threitol (DTT) and 10% (v/v) glycerol in a final volume of 2 ml at 40 °C, 30 min. The initial rate of hydrolysis of nitrocefin was determined by an UV-visible spectrophotometer (Shimadzu, UV-1800, Japan) at 492 nm. Colour changes from yellow to red when nitrocefin hydrolyzed by NDM-1 activity. 1 U corresponds to the amount of enzyme that could generate 1 μ M hydrolyzed nitrocefin per minute by hydrolysis. The susceptibility of *A. baumannii* and recombinant *E. coli* (containing pET28a-NDM-1) plasmids to imipenem, meropenem, cefepime, cefotaxime, ceftazidime, aztreonam, ampicillin, piperacillin, tigecycline, gentamicin, colistin and amikacin were determined using the *E*-test method (bioMérieux, Basingstoke, UK) on Mueller–Hinton agar according to the manufacturer's instructions.

2.6. Steady-state kinetics, IC₅₀ determination and molecular docking

The kinetic parameters were obtained by measuring the initial rate of the reaction at different substrate concentrations. Hydrolysis of the β -lactam antibiotics by NDM-1 was followed by observing changes in absorption resulting from the opening of the β -lactam ring at specific wavelengths for each antibiotics. The kinetic parameters assays were performed at 30 °C using a UV₂₁₈₀₀ spectrophotometer (Mapada, Shanghai, China). Assays were performed in 200 μ L of assay buffer (30 mM HEPES, 10 μ M ZnCl₂, and 2 mM DTT, 0.01% Triton X-100, pH = 7.0). The steady-state kinetic parameters (K_m) were determined three times to evaluate the standard deviation. The K_m was analyzed using in the program of origin 8.0 (OriginLab Corporation, Northampton, MA) to generate Michaelis–Menten and substrate inhibition curves. For the IC₅₀ of these compounds determination, NDM-1 (5 nM) supplemented with 10 μ M ZnSO₄, was pre-incubated with EDTA and AMA (dissolved in DMSO) 20

minutes, then, was mixed with 60 μ M imipenem at 30 °C, and the final concentration of DMSO in the assay was <0.5% (v/v), linear portions of curves were used to analyze data. Assays were read in 96-well microplate format at 293 nm using a Spectramax reader at 37 °C.

The structures of the NDM-1 was obtained by homology modeling (SWISS-MODEL workspace, <https://www.swissmodel.expasy.org/>).²⁰ The three-dimensional structures of the inhibitors were generated using the Chem-office Ultra 11.0 program (Cambridge Soft Corporation, Cambridge, MA, USA).^{20b} Molecular docking was carried out using the Auto-dock 4.0 software. Only ligand molecules were considered to be flexible during the docking, and only the free energy of their best orientation was used to compute the docking free energy.

3. Results

3.1. Emerging of NDM-1 from *Acinetobacter baumannii*

A total of 12 clinical isolates of Gram-negative bacteria, were collected from the sputum of ten patients suffering from pneumonia. Of these, three isolates identified as *Acinetobacter baumannii*. All these *A. baumannii* were resistant to the tested antibiotics, including cephalosporins (Table 1). The *A. baumannii* were resistant to most of β -lactam antibiotics, including ceftazidime, imipenem; meropenem, cefepime, cefotaxime, ceftazidime, aztreonam, ampicillin, piperacillin, and susceptible to colistin, tigecycline, gentamicin; amikacin (Table 1). *A. baumannii* isolates (S001, S002, S003) were positive by the MBL *E*-test. All these *A. baumannii* carries *bla*_{NDM-1} gene validated by PCR screening and sequencing. The sequences of the *bla*_{NDM-1} genes was showing 99.5%, 99.9%, 99.2% (S001, S002, S003), respectively, compared with previously reported genes (NDM-1).⁸

3.2. Overexpression and biochemical characterization of the recombinant NDM-1

In order to achieve high-level overexpression of NDM-1 in *E. coli*, 830-bp DNA fragment including the termination codon and the native signal peptide, encoding NDM-1, was amplified by PCR from DNA of *Acinetobacter baumannii* S002 and cloned into the expression plasmid pET28a (+). Plasmid pET-28a (+)-NDM-1 was confirmed by DNA sequencing and transformed into *E. coli* BL21 (DE3). Recombinant NDM-1 is intracellular, and crude extract was obtained after expressing cells were grown, harvested, and lysed using a cell disrupter. The recombinant NDM-1 protein is an intracellular protein in a soluble and active form. After induction with 0.5 mM IPTG at 30 °C, proteins from

Table 1 Antibiotic susceptibilities of *A. baumannii* (mg L⁻¹)^a

Isolates	IMP	MEM	FEP	CTX	CAZ	ATM	SMP	PIP	TGC	GEN	CST	AMK
S001	>32	>32	256	256	256	256	>256	>256	0.5	1	0.5	8
S002	>32	>32	>256	256	256	256	>256	>256	1	1	0.5	16
S003	>32	>32	256	256	256	64	256	>256	1	>256	0.5	8

^a IMP, imipenem; MEM, meropenem; FEP, cefepime; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; SMP, ampicillin; PIP, piperacillin; TGC, tigecycline; GEN, gentamicin; CST, colistin; AMK, amikacin.






Fig. 1 SDS-PAGE analysis of NDM-1. (A) 10% polyacrylamide gel: Lane 1: control cell containing pET28a (+) plasmid, Lane 2: protein molecular weight standard marker (Takara), Lane 3: lysed expressed cell containing pET28a (+)-*bla*_{NDM-1} plasmid.

control, purified and over-expressing cells were analyzed by SDS-PAGE, and an intense band with a molecular mass of approximately 29 kDa that corresponds to NDM-1 was observed (Fig. 1). The specific activity of the over-expressing cell extract was 17.8 U mg^{-1} , which was 3.8-fold higher than that of the *Acinetobacter baumannii* cells.

Different medium were investigated to determine the NDM-1 activity. Fig. 2A shows the NDM-1 activity and biomass reached maximum values (14.3 U ml^{-1} and 1.32 g L^{-1} , respectively) when SOC was used as the medium source. NDM-1 activity improved by 69.7%, as compared with that in LB medium. The optimal induction phase was carried out during the exponential

growth phase ($\text{OD}_{600} = 0.60$, Fig. 2B). We found that 0.65 mM IPTG were required and the maximum recombinant NDM-1 activity (25.8 U ml^{-1}) was observed with 20 h of induction (Fig. 2C and D). An orthogonal $L_9 (3)$ array experiment was performed to optimize NDM-1 over-expression. The order of the effect of the factors on NDM-1 production was initial $\text{OD}_{600} > \text{IPTG concentration} > \text{induction period}$. The initial cell density was the main factor for NDM-1 production. In this study, the optimal conditions for NDM-1 over-expression were as follows: $\text{OD}_{600} = 0.60$, IPTG 0.65 mM , and induction 20 h (Table 2). The NDM-1 activity was up to maximum values 68.5 U ml^{-1} under the optimal condition, improved by 92.3% as compared with that before optimization (LB medium, 5.3 U ml^{-1}).

3.3. Purification and biochemical characterization of recombinant NDM-1

The recombinant NDM-1 was purified by HisTrapTM FF affinity chromatography, and the specific activity of purified NDM-1 was up to 347.35 U mg^{-1} (Table 3). The optimal pH and pH stability of recombinant NDM-1 were determined within a pH range of 2.0–10.0 (Fig. 3A). The results show that the recombinant NDM-1 had an optimal pH of 7.2. Interestingly, NDM-1 was stable at high-pH, the relative activity of NDM-1 retained 45% at pH = 11. Fig. 3B shows the NDM-1 activity increased with the temperature from 20 to 30 °C and decreased from 30 to 60 °C. The maximum activity of the recombinant NDM-1 was observed at 30 °C. The thermostability experiments of the recombinant NDM-1 showed the enzyme was stable at 10–37 °C, and became unstable when the temperature was above 42 °C (Fig. 3B).

3.4. Inhibitors and β -lactam antibiotic screening

In order to select an excellent antibiotic for inhibitors evaluation and synergistic against the NDM-1 producing *Acinetobacter*




Fig. 2 Expression condition optimized on recombinant NDM-1 activity. (A) Medium, (B) OD_{600} , (C) IPTG, (D) time.



Table 2 Results of the L₉ (3) orthogonal array

Run	Factors			A initial cell density	B induction period (h)	C IPTG (mM)	NDM-1 activity (U ml ⁻¹)
	A	B	C				
1	1	1	1	0.5	15	0.55	18
2	1	2	2	0.5	20	0.65	67
3	1	3	3	0.5	25	0.75	28
4	2	1	2	0.6	15	0.65	43
5	2	2	3	0.6	20	0.75	52
6	2	3	1	0.6	25	0.55	60
7	3	1	3	0.7	15	0.75	48
8	3	2	1	0.7	20	0.55	23
9	3	3	2	0.7	25	0.65	34
k ₁				37.67	36.33	33.67	
k ₂				51.67	47.33	48.00	
k ₃				35.00	40.67	42.67	
Delt				16.67	11.00	14.33	
Ran				1	3	2	

Table 3 Purification of recombinant NDM-1

Steps	Total protein (mg)	Total activity (U)	Specific activity (U mg ⁻¹)	Yield (%)	Purification fold
Crude (0.5 L)	1058.70	33 946.50	32.06	100.00	1.00
Precipitation	589.63	28 250.00	47.91	83.22	1.49
Amicon Ultra-15 10K	116.40	11 024.65	94.71	32.48	2.95
HisTrap	15.75	5470.77	347.35	16.12	10.83

baumannii, kinetic parameters of a representative set of carbapenem, penicillin and cephalosporin β -lactam antibiotic substrates were determined for NDM-1. The results showed that the NDM-1 hydrolyzed all the tested carbapenems (imipenem, meropenem), penicillin (ampicillin, penicillin G, piperacillin); cephalosporins (cefuroxime, ceftizoxime, cefpiramide, ceftazidime, cefoxitin, cefaclor, cephalixin, nitrocefin, cefepime, cephalothin, cefotaxime) (Fig. 4). Of these, the penicillin substrate was all hydrolyzed by the NDM-1. For the tested

cephalosporins, there are significant differences in kinetic parameters. Cefepime has higher K_m (80 μ M), in contrast; the NDM-1 have low K_m values for nitrocefin (1.5 μ M), therefore, nitrocefin has been used for NDM-1 activity determination. Only a small amount of β -lactam antibiotics have poor affinity towards NDM-1, the K_m of cefepime, cefoxitin, imipenem, ceftazidime, meropenem were >60 μ M. Imipenem with a K_m value of 128 μ M, which was higher than the others, was selected as the excellent antibiotic.




Fig. 3 The effect of pH, temperature on the activity of recombinant NDM-1. (A) pH. The optimal pH was determined at 30 °C using various 50 mM buffers, including citrate buffer (pH 2.2, 3.0, 4.0, 5.0), Bis-Tris buffer (pH 6.0, 7.2), Tris-HCl buffer (pH 8.0, 9.0) and glycine-NaOH buffer (pH 9.0, 10.0, 11.0). Relative activity (RA) was calculated and the maximum activity was regarded as 100%. To determine the pH stability, the enzyme was pre-incubated in above buffers with different pH (pH 3.0–12.0) at 30 °C for 18 h, and the RAs were determined in BTB buffer (50 mM Bis-Tris buffer (pH 7.2) containing 50 μ M Zn²⁺, 1 mM 1,4-dithio-DL-threitol and 10% (v/v) glycerol) at 30 °C. (B) Temperature. The optimal temperature was determined in 50 mM Bis-Tris buffer (pH 7.2) at a temperature range from 5 to 70 °C. To determine temperature stability, the NDM-1 was pre-incubated at different temperature (5–70 °C) for 60 min in 50 mM Bis-Tris buffer (pH 7.2), and the residual activity was then determined in the BTB buffer at 30 °C.






Fig. 4 Steady state kinetic parameters of full-length NDM-1 with kinds of representative β -lactam antibiotics. Penicillin (ampicillin, penicillin G, piperacillin); cephalosporins (cefuroxime, ceftizoxime, cefpiramide, ceftazidime, cefoxitin, cefaclor, cephalexin, nitrocefin, cefepime, cephalothin, cefotaxime); carbapenems (imipenem, meropenem).

Our long-term goal is to search for clinically applicable NDM-1-inhibitory agents that interacted with the residue at the active site with the potential of inhibition of all NDMs (NDM-1 and its variants). In order to assess the various classes of metallo-enzyme inhibitors, succinic acid analogues,^{13b}

hydroxamic acids,²¹ ebselen,²² bisthiazolidines,²³ captopril analogues,²⁴ thiols,²⁵ and *N*-hydroxythiazoles,²⁶ triazolythioacetamide,²⁷ EDTA and others were selected as the potential metallo-enzyme inhibitors for screening. The residual activities of NDM-1 were determined and shown in Fig. 5.

Unfortunately, these commercially available β -lactamase inhibitor (clavulanic acid, sulbactam, tazobactam) do not inhibit the NDM-1 effectively. Moreover, it indicated that the majority of the tested inhibitors had residual activities >30%, including succinic acids (S1, S2, S3), hydroxamic acids (H1–H3) and thiols derivatives (T1–T3), captopril, cefaclor, cephalexin, 3-formylchromone. On the other hand, L-captopril, ebselen, aspergillomarasmine A (AMA), EDTA, D-captopril gave residual activities of <20%, especially, ebselen, aspergillomarasmine A (AMA) had residual activities <5% (Fig. 5). Consequently, EDTA, AMA, L-captopril, ebselen, D-captopril were screened by molecule docking, surprisingly, EDTA and AMA had high affinity for NDM-1 with docking energy of $-98.41 \text{ kcal mol}^{-1}$ and $-109.19 \text{ kcal mol}^{-1}$ (Table 4). Herein, EDTA and AMA were further selected as excellent NDM-1 inhibitor. Next, the synergistic inhibition of EDTA and AMA was investigated. The result showed that NDM-1 inhibition increases according to the molar ratio of AMA to EDTA (5 : 1–1 : 2). Of great interest, when the molar ratio of AMA to EDTA reached 1 : 2, the inhibition of NDM-1 was up to 98.5% (Fig. 6A). The working time of AMA–EDTA, AMA and EDTA were 5 min, 20 and 35 min, respectively (Fig. 6B).




Fig. 5 Residual activities (RA) of different types of inhibitors. Residual activities (RA) of different types of inhibitors (A); the structure of the candidate inhibitors (B). Residual activities were tested using NDM-1 (50 pm) with at 100 μM inhibitor (final inhibitor concentration of 10 μM), aspergillomarasmine A (AMA).

Table 4 Effect of inhibitors on the affinity of NDM-1 by molecule docking^a

Inhibitors	Structures	Docking energy (kcal mol ⁻¹)	Inhibitors	Structures	Docking energy (kcal mol ⁻¹)
AMA		-98.41 ± 1.23	D-Captopril		-61.76 ± 0.69
Ebselen		-78.03 ± 0.92	EDTA		-109.19 ± 1.58

^a Molecular docking was carried out using the Auto-dock 4.0 software. Only ligand molecules were considered to be flexible during the docking, and only the free energy of their best orientation was used to compute the docking free energy.






Fig. 6 Effect of the molar ratio of AMA to EDTA on NDM-1 inhibition. The molar ratio of AMA to EDTA (A), inhibition (%) = enzyme activity of NDM-1 (in the absence of inhibitor) – the enzyme activity (after 30 min with inhibitor addition), inhibitor final concentration was 10 μ M. NDM-1 activity curve with time along with the time in the absence or in the presence of different concentrations of each inhibitors (B). The IC₅₀ of different inhibitors (C). Imipenem hydrolysis inhibition in *E. coli* cells producing NDM-1 by AMA : EDTA = 1 : 2 (D), (■) control (no inhibitor), (◆) adding inhibitor (AMA : EDTA = 1 : 2).

AMA, EDTA, and their combination (AMA–EDTA = 1 : 2) were subsequently selected for IC₅₀ determinations. AMA–EDTA was found to be the most potent inhibitor for NDM-1 tested, with IC₅₀ values ranging from 1 to 10 μ M; compared to AMA and EDTA alone, the IC₅₀ of AMA–EDTA (1 : 2) decreased by 88% and 95%, respectively (Fig. 6C). The effect of AMA–EDTA on NDM-1 inhibition has been investigated in presence of

imipenem, imipenem concentration was reduced 99.5% in the absence of inhibitor (AMA : EDTA = 1 : 2), while the imipenem was only reduced by 16% with addition of AMA–EDTA (1 : 2) within 30 min (Fig. 6D). Most interesting, AMA–EDTA could restore the activity of carbapenem (imipenem) when tested against *E. coli* expressing NDM-1 and NDM-1-producing *Acinetobacter baumannii*, with a working time of 120 min and 330 min, respectively (Fig. 7).




Fig. 7 AMA : EDTA restore the *in vitro* activity of imipenem against NDM-1-producing *E. coli* and *Acinetobacter baumannii*. Bacteria were grown at sublethal concentrations of imipenem alone (16 μ g ml⁻¹) or in combination with 100 μ g ml⁻¹ of each compound. Results shown are the mean of three biological replicates.

4. Discussion

Great health risks to human and animals were posed by emerging multi-drug resistant (MDR) bacteria *Acinetobacter baumannii*. We found *Acinetobacter baumannii* was susceptible to colistin, and colistin has been a potent antibiotic to control the NDM-1 bacterial infections. However, it could not be always work. Colistin is destroyed and inactivated by the co-producing NDM-9 and MCR-1 *E. coli*.²⁸ The New Delhi metallo- β -lactamase 1 (NDM-1) and its variants were reported to be resistant to most of the β -lactam antibiotics.²⁹ Although the mechanism and pathways of cephalosporin hydrolysis catalyzed by NDM-1 has been resolved,³⁰ lack of efficient inhibitors to NDM-1 still is a big clinical concern. Therefore, it is meaningful to develop a rapid and efficient method for inhibitors screening to against NDM-1 mutants.

There are two routes for discovering efficient NDM-1 inhibitors. One is rational design of new inhibitors, which is not exist in nature currently, however, new synthesized compounds or newly-discovered drugs (without clinical trials), were lack of the support of clinical trial data, safety of the new inhibitors need to






Fig. 8 The flow chart of antibiotics and the inhibitor screening.

be studied, moreover, R & D period is very long. It is difficult to meet the urgent needs of the current war to against MDR bacteria. The other route is “new use for old drugs”, the old drug has sufficient clinical trial data, high safety and mature synthetic process. The method of inhibiting NDM-1 by adding inhibitors can be rapidly responded to the new NDM-1 variants in a short term, leading to reduce the patient pain and mortality. Towards NDM-1, the inhibitors with high affinity (HI) and the β -lactam antibiotics with low affinity (LA) were selected as the excellent combinations (Fig. 8). This method is expected to be used in drug design (including new inhibitors and drugs) and high-throughput screening.

Aspergillomarasmine A (AMA) was able to completely reserve the antibacterial activity of meropenem against NDM-1.³¹ NDM-1 was inactive while EDTA covalently binded with the cysteine residue at the active site.²² In this context, the two major advantages of EDTA and AMA has been integrated. AMA combined with EDTA can completely reserve the imipenem to fight against NDM-1-producing *E. coli* and *Acinetobacter baumannii*. Imipenem combined with inhibitors (AMA : EDTA = 1 : 2) can kill the NDM-1-producing *E. coli* efficiently. We found NDM-1-producing *Acinetobacter baumannii* is harder to be killed than that of *E. coli*, and the working time of NDM-1-producing *Acinetobacter baumannii* was 2.75 times of expressing NDM-1 *E. coli*. It may be caused by the difference of the outer membrane permeability. The outer membrane in *A. baumannii* is less permeable to antimicrobial agents than that in *Escherichia coli*.^{32,33} Outer membrane permeability of *A. baumannii* decreased by its small number and size of porins.³⁴

Moreover, AMA is a peptide, which can be degraded by biological enzymes. AMA can be obtained by fermentation with a low production cost and more benefit to human beings. Furthermore, efficient and low toxicity new inhibitors (new structures) from the extract of natural plants and marine microorganisms and AMA remodeling will be tried in subsequent research. In the present study, the NDM-1 from *Acinetobacter baumannii* was overexpressed in *E. coli* BL21 (DE3), however, the activity of NDM-1 was very low. Then, conditions were further optimized by an orthogonal array experiment, and high purity of recombinant NDM-1 was obtained. NDM-1 was

stable ($5 < \text{pH} < 11$, temperature $< 45^\circ\text{C}$), which is expected to be applied to resolve the problem of antibiotics residues, and antibiotic leakage, antibiotic testing, biological sensor. The NDM-1 variants from *A. baumannii* S001 and S003, may have some new properties, will be investigated in future.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

This work was supported by Key Technology Program of Zhongshan (No. 2015B1028).

References

- (a) S. N. Richter, I. Frasson, E. Franchin, C. Bergo, E. Lavezzo, L. Barzon, A. Cavallaro and G. Palù, *Gut Pathog.*, 2012, **4**, 1; (b) A. U. Khan, L. Maryam and R. Zarrilli, *BMC Microbiol.*, 2017, **17**, 101.
- S. M. Drawz and R. A. Bonomo, *Clin. Microbiol. Rev.*, 2010, **23**, 160.
- T. Palzkill, *Ann. N. Y. Acad. Sci.*, 2013, **1277**, 91.
- C. Bebrone, *Biochem. Pharmacol.*, 2007, **74**, 1686.
- S. D. Lahiri, S. Mangani, T. Durandreville, M. Benvenuti, F. D. Luca, G. Sanyal and J. D. Docquier, *Antimicrob. Agents Chemother.*, 2013, **57**, 2496.
- C. Bebrone, P. Lassaux, L. Vercheval, J. S. Sohler, A. Jehaes, E. Sauvage and M. Galleni, *Drugs*, 2010, **70**, 651.
- (a) K. Bush, *J. Infect. Chemother.*, 2013, **19**, 549; (b) N. Tijet, D. Boyd, S. N. Patel, M. R. Mulvey and R. G. Melano, *Antimicrob. Agents Chemother.*, 2013, **57**, 4578.
- D. Yong, M. A. Toleman, C. G. Giske, H. S. Cho, K. Sundman, K. Lee and T. R. Walsh, *Antimicrob. Agents Chemother.*, 2009, **53**, 5046.
- G. Bushnell, F. Mitrani-Gold and L. M. Mundy, *Int. J. Infect. Dis.*, 2013, **17**, e325.
- (a) H. Grundmann, D. M. Livermore, C. G. Giske, R. Canton, G. M. Rossolini, J. Campos, A. Vatsopoulos, M. Gniadkowski, A. Toth and Y. Pfeifer, *Eurosurveillance*, 2010, **15**, 22; (b) S. Chatterjee, A. Mondal, S. Mitra and S. Basu, *J. Antimicrob. Chemother.*, 2017, dkw131; (c) K. Karthikeyan, M. A. Thirunarayan and P. Krishnan, *J. Antimicrob. Chemother.*, 2010, **65**, 2253.
- T. R. Walsh, J. Weeks, D. M. Livermore and M. A. Toleman, *Lancet Infect. Dis.*, 2011, **11**, 355.
- A. Pruden, D. G. Larsson, A. Amézquita, P. Collignon, K. K. Brandt, D. W. Graham, J. M. Lazorchak, S. Suzuki, P. Silley and J. R. Snape, *Environ. Health Perspect.*, 2013, **121**, 878.
- (a) L. B. H. Pinhong Chen, R. L. Mikulski, L. Deng, S. Sundriyal and T. Palzkill, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 6229; (b) J. H. Toney, G. G. Hammond, P. M. D. Fitzgerald, N. Sharma, J. M. Balkovec, G. P. Rouen, S. H. Olson, M. L. Hammond, M. L. Greenlee and Y. Gao, *J. Biol. Chem.*, 2001, **276**, 31913.



- 14 W. T, S. SA, M. D, S. TP, F. JR, S. M, F. JM, B. C, S. KB and H. PS, *ACS Med. Chem. Lett.*, 2010, **1**, 150.
- 15 B. M. R. Liénard, G. Garau, L. Horsfall, A. I. Karsisiotis, C. Damblon, P. Lassaux, C. Papamicael, G. C. K. Roberts, M. Galleni and O. Dideberg, *Org. Biomol. Chem.*, 2008, **6**, 2282.
- 16 (a) M. W. Walter, A. Felici, M. Galleni, R. P. Soto, R. M. Adlington and J. E. Baldwin, *Bioorg. Med. Chem. Lett.*, 1996, **6**, 2455; (b) W. Fast and L. D. Sutton, *Biochim. Biophys. Acta, Proteins Proteomics*, 2013, **1834**, 1648.
- 17 D. S. Uppu, S. Samaddar, C. Ghosh, K. Paramanandham, B. R. Shome and J. Haldar, *Biomaterials*, 2016, **74**, 131.
- 18 M. M. Bradford, *Anal. Biochem.*, 1976, **72**, 248.
- 19 C. H. O'Callaghan, A. Morris, S. M. Kirby and A. H. Shingler, *Antimicrob. Agents Chemother.*, 1972, **1**, 283.
- 20 (a) J. Wu, H. Wang, B. Yang, W. Song, C. Liang and L. Liu, *RSC Adv.*, 2017, **7**, 38264; (b) M. Biasini, S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, F. Kiefer, T. C. Gallo, M. Bertonni and L. Bordoli, *Nucleic Acids Res.*, 2014, **42**, W252.
- 21 B. M. Liénard, L. E. Horsfall, M. Galleni, J. M. Frère and C. J. Schofield, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 964.
- 22 J. Chiou, S. Wan, K. F. Chan, P. K. So, D. He, E. W. Chan, T. H. Chan, K. Y. Wong, J. Tao and S. Chen, *Chem. Commun.*, 2015, **51**, 9543.
- 23 M. M. González, M. Kosmopoulou, M. F. Mojica, V. Castillo, P. Hinchliffe, I. Pettinati, J. Brem, C. J. Schofield, G. Mahler and R. A. Bonomo, *ACS Infect. Dis.*, 2015, **1**, 544.
- 24 (a) G. Yu, W. Jing, G. Niu, W. Shui, Y. Sun, H. Zhou, Y. Zhang, Y. Cheng, Z. Lou and Z. Rao, *Protein Cell*, 2011, **2**, 384; (b) N. Li, Y. Xu, X. Qiang, C. Bai, T. Wang, W. Lei, D. He, N. Xie, L. Li and W. Jing, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 386; (c) D. T. King, L. J. Worrall, R. Gruninger and N. C. Strynadka, *J. Am. Chem. Soc.*, 2012, **134**, 11362.
- 25 S. Siemann, A. J. Clarke, T. Viswanatha and G. I. Dmitrienko, *Biochemistry*, 2003, **42**, 1673.
- 26 C. M. Tegley, V. N. Viswanadhan, K. Biswas, M. J. Frohn, T. A. Peterkin, C. Chang, R. W. Bürli, J. H. Dao, H. Veith and N. Rogers, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 3925.
- 27 (a) L. Zhai, Y. L. Zhang, J. S. Kang, P. Oelschlaeger, L. Xiao, S. S. Nie and K. W. Yang, *ACS Medicinal Chemistry Letters*, 2016, **7**, 413; (b) P. W. Thomas, T. S. Michael Cammarata, J. S. Brodbelt, P. Hodder and W. Fast, *Bioorg. Med. Chem.*, 2013, **21**, 3138.
- 28 X. Yao, Y. Doi, L. Zeng, L. Lv and J. H. Liu, *Lancet Infect. Dis.*, 2016, **16**, 288.
- 29 K. K. Kumarasamy, M. A. Toleman, T. R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, U. Chaudhary, M. Doumith, C. G. Giske and S. Irfan, *Lancet Infect. Dis.*, 2010, **10**, 578.
- 30 H. Feng, J. Ding, D. Zhu, X. Liu, X. Xu, Y. Zhang, S. Zang, D. C. Wang and W. Liu, *J. Am. Chem. Soc.*, 2014, **136**, 14694.
- 31 A. M. King, S. A. Reid-Yu, W. Wang, D. T. King, G. De Pascale, N. C. Strynadka, T. R. Walsh, B. K. Coombes and G. D. Wright, *Nature*, 2014, **510**, 503.
- 32 J. Hrabák, E. Chudáčková and R. Walková, *Clin. Microbiol. Rev.*, 2013, **26**, 103.
- 33 J. Vila, S. Martí and J. Sánchez-Céspedes, *Journal of Antimicrobial Chemotherapy*, 2007, **59**, 1210.
- 34 M. Obara and T. Nakae, *J. Antimicrob. Chemother.*, 1991, **28**, 791.

